Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-02-06
2010-02-09
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254050, C544S364000, C544S366000
Reexamination Certificate
active
07659276
ABSTRACT:
Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula Iwherein A, W, X, Z, R1-R3, and R8are as defined in the specification, are provided. Also provided are methods of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, comprising administering to a subject in need of such treatment or prevention a compound of Formula I.
REFERENCES:
patent: 6472394 (2002-10-01), McKittrick et al.
patent: 6552188 (2003-04-01), Kodama et al.
patent: 7078414 (2006-07-01), Kleemann et al.
patent: 7078430 (2006-07-01), Kumar et al.
patent: 7087638 (2006-08-01), Walter et al.
patent: 7091235 (2006-08-01), Friedman et al.
patent: 2002/0182655 (2002-12-01), Kostenis et al.
patent: 2003/0229119 (2003-12-01), Kym et al.
patent: 2 356 412 (2000-07-01), None
patent: 2 383 147 (2001-03-01), None
patent: 0 127 124 (1984-12-01), None
patent: 96/14307 (1996-05-01), None
patent: 98/03492 (1998-01-01), None
patent: 98/03493 (1998-01-01), None
patent: 98/03494 (1998-01-01), None
patent: 98/10068 (1998-03-01), None
patent: 00/39279 (2000-07-01), None
patent: 01/05947 (2001-01-01), None
patent: 01/21577 (2001-03-01), None
patent: 02/04433 (2002-01-01), None
patent: 02/094799 (2002-11-01), None
patent: 03/015769 (2003-02-01), None
patent: 03/045313 (2003-06-01), None
patent: 03/073999 (2003-09-01), None
patent: 03/087044 (2003-10-01), None
patent: 03/087046 (2003-10-01), None
Carpenter et al. Expert Opinion in Therapeutic Patents, vol. 12(11) p. 1639-1646 (2002).
Bednarek et al. Journal of Biological Chemistry, vol. 277, p. 13821-13826 (2002).
Dyke et al. Expert Opin.Ther.Patents, vol. 15, p. 1303-1313 (2005).
Banker, G. S., et al., Modern Pharmaceuticals, 1996, p. 596, Third Edition, Revised and Expanded.
Edwards, P. D., et al., “Discovery and Biological Activity of Orally Active Peptidyl Trifluoromethyl Ketone Inhibitors of Human Neutrophil Elastase,” Journal of Medicinal Chemistry, 1997, pp. 1876-1885, vol. 40, No. 12.
International Search Report, PCT/US04/25970, dated Mar. 3, 2005, 3 pages.
Lythgoe, D. J., Abstract of WO 1992/469592.
Marsh, D.J. et al., “Melanin-Concentratiing Hormone 1 Receptor-Deficient Mice Are Lean, Hyperactive, and Hyperphagic and Have Altered Metabolism”, PNAS, (2002), pp. 3240-3245, vol. 99:5.
Nabeya, A., et al., “Diaziridines. 2. Isomerization of N-Carbamoyldiaziridines,” Journal of Organic Chemistry, 1979, pp. 3935-3938, vol. 44, No. 22.
Stamos, I. K., “Aldehyde-Enamines from α-Oxocarboxylic Acids. A Facile and General Route to Aldehydes Via Decarboxylation of α-Oxocarboxylic Acids Carrying β-Hydrogens,” Tetrahedron Letters, 1982, pp. 459-462, vol. 23, No. 4.
Supplementary Partial European Search Report, PCT/US2004/025970, dated Oct. 31, 2007, 6 pages.
Walker, G. N., et al., “Synthesis of Varied Heterocyclic and Substituted Aryl Alkyl Secondary Amines, Related Schiff Bases, and Amides,” Journal of Medicinal Chemistry, Jul. 1966, pp. 624-630, vol. 9.
Weikert, R. J., et al., “Synthesis and Anthelmintic Activity of 3′-Benzoylurea Derivatives of 6-Phenyl-2,3,5,6-Tetrahydroimidazo[2,1-b]thiazole,” Journal of Medicinal Chemistry, 1991, pp. 1630-1633, vol. 34, No. 5.
Wissner, A., et al., “Analogues of Platelet Activating Factor. 7. Bis-Aryl Amide and Bis-Aryl Urea Receptor Antagonists of PAF,” Journal of Medicinal Chemistry, 1992, pp. 4779-4789, vol. 35, No. 26.
Wolff, M. E., Burger's Medicinal Chemistry and Drug Discovery, 1995, pp. 975-977, Fifth Edition, vol. 1: Principles and Practice.
Balow Guity
Hulme Christopher
Ma Vu
Nixey Thomas
Tempest Paul
Amgen Inc.
Bernhardt Emily
Senniger Powers LLP
LandOfFree
Melanin concentrating hormone receptor antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Melanin concentrating hormone receptor antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanin concentrating hormone receptor antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4210298